

PROGRAMME

	WEDNESDAY 26	OCTOBER 2022	
	REGISTI	RATION	
	ROOM 111+112	ROOM 211 + 212	
10.00	Clinical Trial Methodology Workshop		
12.00	Poster Viewing (Exibition Hall)/ Lunch and Coffee Break		
13.00	Welcome		(00:
13.05	Michel Clavel Lecture		- 20
13.50	Keynote Lecture		00
14.45	Plenary Session 1		(12
14.45	STING Agonists		Exhibition (12.00 – 20:00)
16.15	Mini symposium	Mini Symposium	
16.15 - 17.45	ADC Variety	Drug Development of Mutant Specific versus Target Selective Inhibitors	EXF
18:00 -20:00	"Welcome Reception (Exhibition	n and Poster Viewing on Hall)"	

	THURSDAY 27 C	OCTOBER 2022	
	ROOM 111+112	ROOM 211 + 212	
	Plenary Session 2		
8.00	Allogeneic Genetically Engineered Cells for ACT		
9.30	Coffee Break		
10.00	Plenary Session 3		((
10.00	Proffered Papers		
11.00	Plenary Session 4		(00
11.30	Emerging New Targets		- 17:
13.00	Poster Viewing (Exibition Hall)/ Lunch and Coffee Break		
	Workshop 1	Workshop 2	60)
16.15	Drug Development in Low-Middle Income Countries - Challenges and Opportunities	Using ctDNA in Directing Therapy of Advanced Cancer	Exhibition (09:30 – 17:00)
	Coffee Break		<u>X</u>
16.15	Workshop 3	Workshop 4	
16.15 - 17.45	Al and Computational Analysis	Liquid Biomarker and Single-Cell Ana- lysis in Cancer Research	



PROGRAMME

	FRIDAY 28 OC	TOBER 2022	
	ROOM 111+112	ROOM 211 + 212	
8.00	Plenary Session 5		
	Project Optimus from the FDA: How Will This Affect Clinical Trials and Drug De- velopment?		
8.30	Coffee Break		
10.00	Workshop 5	Workshop 6	
	Modernising Eligibility Criteria for Early Phase Oncology Clinical Trials	How To Optimise The Use Of Preclinical Models for Drug Development	(09:30 – 17:00)
11.30	Plenary Session 6		
	New Drugs on the Horizon		
13.00	Poster Viewing (Exibition Hall)/ Lunch and Coffee Break		
15.00	Plenary session 7		
- 16.30	Late Breaking Proffered Papers		